Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
PureTech founder steps down as CEO to lead SeaPort spin-off
(Sharecast News) - Clinical-stage biotherapeutics group PureTech has announced that its founding chief executive is to step down to lead SeaPort Therapeutics, a PureTech company she founded that has just raised $100m in Series A financing. Seaport will be led by Daphne Zohar, who has run PureTech since its foundation in 2005, along Steven Paul, the former CEO of Karuna Therapeutics - the PureTech spin-off that was acquired by Briistol Myers Squibb for $14bn earlier this year.
Seaport was established by PureTech to advance certain neuropsychiatric programs and will be 61.5% owned by the company following the Series A.
PureTech said it has internally advanced Seaport's neuropsychiatric medicines programs "to a key inflection point such that the pipeline can now drive value for PureTech through an equity stake and license consideration". As such, PureTech can now share the costs of later-stage development with outside investors and direct additional resources elsewhere in the business.
This same approach, part of PureTech's 'hub-and-spoke strategy', has resulted in $1.1bn in gross proceeds so far from its stake in Karuna. PureTech still receives royalties from Karuna as well as certain milestone payments.
As part of the transition, Zohar will formally step down from the board but stay on as a senior advisor, while long-term PureTech senior executive and biotech veteran Bharratt Chowrira will succeed her as CEO, effective Tuesday.
Meanwhile, Eric Elenko, a PureTech co-founder and current chief innovation officer, has been promoted to the role of president.
"I am excited to step into the CEO role and to lead PureTech through this next phase of its evolution," Chowrira said.
"We have demonstrated the evergreen success of our hub-and-spoke R&D model of venture creation, where we are able to recycle proceeds from our founded entities into both the funding of our current and future programs to change patients' lives and capital returns for shareholders."
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.